[Skip to content]

European Parkinson's Disease Association
Search our Site

Research papers


Mechanisms research papers

  • Journal of Neural Transmission Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's diseaseObjectives were to investigate plasma concentrations of repulsive guidance molecule A, levodopa, cysteine and cysteinyl-glycine before and 1 h after levodopa application in patients with Parkinson's disease. 01 April 2016
  • Neural Regeneration Research An open-label pilot study with high-dose thiamine in Parkinson's diseaseRecent data showed that in some inherited and degenerative diseases of the nervous system the pathogenesis of the symptoms could be linked to a focal deficiency of thiamine (vitamin B1) due either to dysfunction of the intracellular thiamine transport or to structural enzymatic abnormalities. Thiamine is a cofactor of enzymes involved in fundamental pathways of the energetic cell metabolism, particularly critical in glucose metabolism. 01 April 2016
  • Parkinsonism & Related Disorders Volume 25 Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonismConclusion: Illicit use of amphetamines is associated with abnormal substantia nigra morphology and subtle clinical signs of parkinsonism. The results support epidemiological findings linking use of amphetamines, particularly methamphetamine, with increased risk of developing Parkinson's disease later in life. 01 April 2016
  • European Journal of Neurology Adjustment disorder and risk of Parkinson's diseaseDuring follow-up, 119 patients developed PD, versus 64 expected, corresponding to a standardized incidence ratio of 1.84 (95% confidence interval 1.53, 2.20). Consistent results were observed after stratification on potential risk factors, including depression and anxiety. 01 April 2016
  • Neurology Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriersConclusion: Elevated ratio of phosphorylated Ser-1292 LRRK2 to total LRRK2 in urine exosomes predicted LRRK2 mutation status and PD risk among LRRK2 mutation carriers. Future studies may explore whether interventions that reduce this ratio may also reduce PD risk. 15 March 2016
  • Movement Disorders Volume 31 Issue 3 Neuroleptic-induced Parkinsonism: Clinicopathological studyThis study shows that reversal of parkinsonism after discontinuing offending drugs does not indicate absence of underlying pathology. Neuroleptics can unmask preclinical PD in patients with insufficient SN damage for the disease to manifest clinically. Though the mechanism of sustained parkinsonian features after discontinuing neuroleptics remains to be established, it is unlikely that dopamine receptor block leads to retrograde SN neuronal degeneration. Furthermore, l-dopa does not appear to be toxic to SN 15 March 2016
  • Movement Disorders Volume 31 Issue 1 Lewy body pathology involves the olfactory cells in Parkinson's disease and related disordersResults: Lewy body pathology was detected in the olfactory cells of the olfactory epithelium in a single patient with incidental Lewy body disease and in six patients with PD, but it was not detected in patients who had dementia with Lewy bodies. 15 March 2016
  • Movement Disorders Volume 31 Issue 3 How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatumIn a recent computational study authors modeled the effects of progressive denervation, including changes in the dynamics of interstitial DA and also adaptive or compensatory changes in postsynaptic responsiveness to DA signaling in the course of progressive nigrostriatal degeneration. In particular, we found that failure of DA signaling can occur by different mechanisms at different disease stages. 15 March 2016
  • Movement Disorders Volume 31 Issue 3 Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson's DiseaseInflammasomes, which mediate the activation of caspase-1 and maturation of IL-1β and IL-18, have been unambiguously verified to participate in many diseases, such as lung diseases, infectious diseases and Alzheimer's disease, but the relation between Parkinson's disease and inflammasomes is poorly understood. 15 March 2016
  • npj Parkinson's Disease SCARB2 variants and glucocerebrosidase activity in Parkinson's diseaseIn view of its ability to explain the most frequent motor symptoms of Parkinson's Disease (PD), degeneration of dopaminergic neurons has been considered one of the disease's main pathophysiological features. Several studies have shown that neurodegeneration also affects noradrenergic, serotoninergic, cholinergic and other monoaminergic neuronal populations. In this work, the characteristics of cholinergic deficits in PD and their clinical correlates are reviewed 10 March 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]